<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04912167</url>
  </required_header>
  <id_info>
    <org_study_id>WestChinaH-CVD-003</org_study_id>
    <nct_id>NCT04912167</nct_id>
  </id_info>
  <brief_title>The Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction</brief_title>
  <acronym>PERI-STEMI</acronym>
  <official_title>A Multi-center, Prospective Randomized Controlled Trial on the Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West China Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the PERI-STEMI trial is to assess whether sacubitril-valsartan is&#xD;
      more effective in preventing adverse LV remodeling for patients with ST-elevation myocardial&#xD;
      infarction (STEMI) than enalapril.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">June 2026</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LV remodeling index on CMR</measure>
    <time_frame>6 months</time_frame>
    <description>change of the indexed LV mass (Î” LVmassi) from baseline to 6-month follow-up on CMR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>left ventricular (LV) ejection fraction</measure>
    <time_frame>6 months</time_frame>
    <description>left ventricular ejection fraction indexes at the 6-month CMR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>global peak LV longitudinal strain</measure>
    <time_frame>6 months</time_frame>
    <description>global peak LV longitudinal strain at the 6-month CMR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myocardial fibrosis</measure>
    <time_frame>6 months</time_frame>
    <description>extracelluar volume measured through T1 mapping sequence at the 6-month CMR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the first occurrence of a composite endpoint of adverse clinical events</measure>
    <time_frame>up to approximately 60 months</time_frame>
    <description>including all deaths (cardiac death vs non-cardiac death), non-fatal myocardial re-infarction, hospitalization for worsening heart failure or need for advanced HF therapies (hospital stay &gt; 24 hours)(e.g., intravenous use of inotropes, left ventricular assist device placement, or cardiac transplantation)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">376</enrollment>
  <condition>STEMI</condition>
  <arm_group>
    <arm_group_label>ARNI-Sacubitril-Valsartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients randomized to angiotensin receptor neprilysin inhibitor (ARNI) group will receive 2 doses of angiotensin receptor blocker (ARB) to ensure a minimum 36-hour washout period prior to initiation of ARNI therapy, and then be started with the first dose or sacubitril-valsartan.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACEI-Enalapril</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients randomized to angiotensin-converting enzyme inhibitor (ACEI) group will directly start with the first dose of enalapril</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sacubitril-Valsartan</intervention_name>
    <description>After initiation of the treatment of sacubitril/valsartan, the dose of the medicine will be titrated to a target level based on the systolic blood pressure of the patients. (24/26 mg, 49/51 mg and 97/103 mg, twice daily)</description>
    <arm_group_label>ARNI-Sacubitril-Valsartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enalapril</intervention_name>
    <description>After initiation of the treatment of enalapril, the dose of the medicine will be titrated to a target level based on the systolic blood pressure of the patients. (2.5 mg, 5 mg, and 10 mg,twice daily)</description>
    <arm_group_label>ACEI-Enalapril</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
    <description>For patients who were previously treated with ACEI and receiving the last dose of that agent during the last 36 hours prior to randomization, Valsartan (VAL489) 40 mg and 80 mg tablets, two doses for 1 day was used.</description>
    <arm_group_label>ARNI-Sacubitril-Valsartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged between 18 - 75 years old&#xD;
&#xD;
          -  First-time ST-segment elevation myocardial infarction based on the newest ESC&#xD;
             guidelines&#xD;
&#xD;
          -  Timely primary percutaneous coronary intervention within 12 hours from onset&#xD;
&#xD;
          -  Written informed consent acquired&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known history of or persistent clinical chronic heart failure prior to randomization&#xD;
&#xD;
          -  Previous use of ARNI, or intolerance or contraindications to study drugs including&#xD;
             ARNI or ACEI&#xD;
&#xD;
          -  History of significant chronic coronary obstruction and adverse ventricular remodeling&#xD;
&#xD;
          -  History of any cardiomyopathy, valvular heart disease, congenital heart disease, stent&#xD;
             or CABG, or planned open-heart surgery within 3 months&#xD;
&#xD;
          -  History of hepatic impairment or history of cirrhosis with evidence of portal&#xD;
             hypertension&#xD;
&#xD;
          -  History of chronic renal dysfunction, or eGFR &lt; 30 ml/min/1.73 m2&#xD;
&#xD;
          -  History of malignancy and with a life span less than one year&#xD;
&#xD;
          -  Patients with a known history of angioedema related to previous ACEIs/ARB therapy.&#xD;
&#xD;
          -  With contraindication to MRI examination (pacemaker and claustrophobia) or cannot&#xD;
             finish breath-holding when lying on the examination bed&#xD;
&#xD;
          -  Pregnancy or nursing women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>621000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 26, 2021</study_first_submitted>
  <study_first_submitted_qc>May 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2021</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>Yong He</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>ST-elevation myocardial infarction (STEMI)</keyword>
  <keyword>cardiovascular magnetic resonance (CMR)</keyword>
  <keyword>angiotensin receptor neprilysin inhibitor (ARNI)</keyword>
  <keyword>angiotensin-converting enzyme inhibitor (ACEI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Ventricular Remodeling</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Enalapril</mesh_term>
    <mesh_term>Sacubitril and valsartan sodium hydrate drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

